Our long-term research interest is to improve the outcome for children with neuroblastoma. We are conducting laboratory-based research focused on understanding the cellular pathways that drive clinically aggressive neuroblastoma growth in order to identify actionable mutations that can be targeted and tested in clinical trials. We have an active collaboration with Drs. Chuan He and Lucy Godley investigating the epigenetic landscape of neuroblastoma. We are also collaborating with Dr. Sam Volchenboum and Dr. Robert Grossman to build an International Neuroblastoma Risk Group (INRG) Data Commons that contain phenotype data on a large cohort of neuroblastoma patients diagnosed around the world. The database was built with technology that allows connections with other databases that contain clinical and genomic information on patients with neuroblastoma diagnosed around the world. These data are available to investigators for data mining studies. Currently, clinical information on >20,000 patients with neuroblastoma are included in the INRG Data Commons. More than 20 research projects have been performed, and many of which would not have been possible with smaller patient cohorts.
Northwestern University
Chicago, Illinois
- Fellow in Pediatric Hematology/Oncology
1987
Michael Reese Hospital and Medical Center
Chicago, Illinois
- Resident in Pediatrics
1984
University of Illinois Medical School
Chicago, Illinois
MD
1980
Northwestern University
Evanston, Illinoins
BA - Biology
1976
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 07; 116(6):885-894.
PMID: 38460547
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. Res Sq. 2024 Jun 04.
PMID: 38883758
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug; 71(8):e31089.
PMID: 38822537
Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module.
Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module. JCO Clin Cancer Inform. 2024 May; 8:e2400009.
PMID: 38815188
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation.
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024 May 28; 43(5):114165.
PMID: 38691450
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111.
PMID: 38100619
In Memoriam: Sharon B. Murphy, MD (1943-2023).
In Memoriam: Sharon B. Murphy, MD (1943-2023). Pediatr Blood Cancer. 2024 Feb; 71(2):e30797.
PMID: 38037198
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.
PMID: 37859597
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. bioRxiv. 2023 Sep 01.
PMID: 37693610
Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.
Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades. EJC Paediatr Oncol. 2023 Dec; 2.
PMID: 38213818
AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
University of Chicago
2019
The Samuel Spector Award for Mentorship, Department of Pediatrics
University of Chicago
2018
American Society of Clinical Oncology Pediatric Oncology Award
2016
Fellow of the American Society of Clinical Oncology (FASCO)
2016
Senior Faculty Scholar in the Bucksbaum Institute for Clinical Excellence
University of Chicago
2014
Association for Women in Science (AWIS) Chicago Innovator Award
2012
Treasurer, American Society of Clinical Oncology
2012 - 2015
Pritzker Scholar
University of Chicago
2012